Celcuity (CELC) closed at $66.79 on November 6, 2026, up 4.3% from the previous close, on volume of 979,657 shares (30-day average 1,620,832).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Calendar Put Spread | 18-Dec-26 : 15-Jan-27 65 P | 2,980 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Cantor Fitzgerald Sticks to Their Buy Rating for Celcuity (CELC)
TipRanks (Fri, 6-Nov 9:46 AM ET)
Celcuity Non-GAAP EPS of -$1.21 beats by $0.32
Seeking Alpha News (Thu, 5-Nov 5:40 PM ET)
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 5-Nov 10:00 AM ET)
Celcuity To Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 8:30 AM ET)
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Globe Newswire (Thu, 29-Oct 8:30 AM ET)
Globe Newswire (Sat, 24-Oct 4:15 AM ET)
Globe Newswire (Fri, 23-Oct 9:15 AM ET)
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Celcuity Appoints David Gryska To Its Board Of Directors
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of November 6, 2026, CELC stock price climbed to $66.79 with 979,657 million shares trading.
CELC has a beta of 1.88, meaning it tends to be more sensitive to market movements. CELC has a correlation of 0.12 to the broad based SPY ETF.
CELC has a market cap of $3.27 billion. This is considered a Mid Cap stock.
Last quarter Celcuity reported $0 in Revenue and -$1.21 earnings per share. This fell short of revenue expectation by $-881,280 and exceeded earnings estimates by $.31.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CELC has underperformed the market in the last year with a return of -10.0%, while the SPY ETF gained +10.8%. In the last 3 month period, CELC fell short of the market, returning -28.4%, while SPY returned -4.1%. However, in the most recent 2 weeks CELC has outperformed the stock market by returning +2.4%, while SPY returned -3.2%.
CELC support price is $61.44 and resistance is $66.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.
